ライフサイエンスコーパス: echocardiographic

1 lysis is to derive objective two-dimensional echocardiographic (2DE) criteria to define CCM associate

2 This study sought to characterize the echocardiographic abnormalities associated with myocardi

3 markers and an increased prevalence of major echocardiographic abnormalities that included left ventr

4 reased in-hospital mortality particularly if echocardiographic abnormalities were present.

5 Carotid artery and echocardiographic abnormalities, and incidence of transi

6 so display greater structural and functional echocardiographic abnormalities.

7 bundle branch block morphology and no ECG or echocardiographic abnormalities.

8 In these patients, the most common echocardiographic abnormality at follow-up was RV functi

9 A novel echocardiographic algorithm was implemented for grading

10 Echocardiographic analysis of pressure overloaded hearts

11 However, morphometric and echocardiographic analysis revealed massive cardiac hype

12 Serial echocardiographic analysis reveals that within 2 weeks o

13 Transthoracic echocardiographic analysis showed a significant improvem

14 Echocardiographic and catheterization data were obtained

15 Echocardiographic and clinical data of patients with mod

16 The 2 groups had similar baseline echocardiographic and electrocardiographic characteristi

17 Echocardiographic and electrocardiographic findings were

18 Echocardiographic and hemodynamic data were obtained fro

19 iously published scores and known individual echocardiographic and hemodynamic markers of RHF.

20 Further, echocardiographic and immunohistochemical analyses of re

21 Agreement between echocardiographic and invasive measures of pulmonary pre

22 t al published a study assessing laboratory, echocardiographic and right heart catheter based paramet

23 n cohorts of patients with heart failure and echocardiographic and/or cardiac magnetic resonance imag

24 Clinical, electrocardiographic, echocardiographic, and cardiac MRI data from 22 individu

25 nI) concentrations and electrocardiographic, echocardiographic, and clinical characteristics were ass

26 Clinical, echocardiographic, and functional outcomes at 1 year wer

27 ng data extracted from clinical, laboratory, echocardiographic, and genetic assessments.

28 Clinical, echocardiographic, and health-status outcomes were follo

29 he IE Study Group according to the clinical, echocardiographic, and microbiologic findings.

30 This study analyzed clinical, echocardiographic, and outcome data prospectively collec

31 trospectively analyzed the clinical, Doppler echocardiographic, and outcome data that were prospectiv

32 nd white men and women-collected phenotypic, echocardiographic, and outcomes data at the year 5 and y

33 Electrocardiographic, echocardiographic, and serum biomarkers of cardiac damag

34 Echocardiographic assessment included RV-to-left ventric

35 Comprehensive echocardiographic assessment including left ventricular

36 146) underwent invasive exercise testing and echocardiographic assessment of cardiac structure, funct

37 easures of coronary artery calcification and echocardiographic assessment of left ventricular systoli

38 Echocardiographic assessment of LVDD by echocardiography

39 Invasive hemodynamic and echocardiographic assessment was performed on galectin-3

40 ients identified, 186 patients with complete echocardiographic assessment were included in the analys

41 ventricular (LV) and LA volumes underwent 3D echocardiographic assessment, and signal-averaged electr

42 y were assessed by clinical, laboratory, and echocardiographic assessments performed at pre-, mid- an

43 transplantation), adjusting for clinical and echocardiographic associates with mortality and major co

44 sistance index (SVRI) was estimated from the echocardiographic cardiac index and the mean arterial pr

45 ng the different ICUs, the mean bias between echocardiographic cardiac output and MostCare cardiac ou

46 A total of 400 paired echocardiographic cardiac output and MostCare cardiac ou

47 One echocardiographic cardiac output measurement was compare

48 We performed baseline echocardiographic, cardiac catheterization, and serum NT

49 Simultaneous echocardiographic-catheterization studies were prospecti

50 of NIV and CPAP on structural and functional echocardiographic changes.Methods: At baseline and annua

51 We examined clinical and echocardiographic characteristics and outcomes in the I-

52 who also had >=Mod TR had worse clinical and echocardiographic characteristics and worse clinical out

53 howed that young and aged HCM mice displayed echocardiographic characteristics of the heart disease c

54 This study compared clinical and echocardiographic characteristics, as well as mortality

55 cation process for the COAPT trial, baseline echocardiographic characteristics, changes over time, an

56 c information over clinical and conventional echocardiographic characteristics.

57 hythmia (24-h Holter monitoring) and Doppler-echocardiographic characterization, was identified.

58 Clinical, echocardiographic, computed tomographic, and angiographi

59 ation, including adjustment for clinical and echocardiographic confounders (OR 1.89; 95% CI 1.50 to 2

60 duct labeling for the commercially available echocardiographic contrast agents (ECA) Definity and Opt

61 yocardial thickening (18/51) and spontaneous echocardiographic contrast and thrombi formation (16/51)

62 Echocardiographic core analysis after 6 months showed mi

63 An independent echocardiographic core laboratory evaluated all echocard

64 The clinical events committee and echocardiographic core laboratory methods were the same

65 mTFC echocardiographic criteria are significantly different b

66 hy screening based on World Heart Federation echocardiographic criteria holds promise to identify pat

67 Strict application of these echocardiographic criteria should enable the COAPT resul

68 mitral regurgitation, selected using strict echocardiographic criteria, benefitted from TMVr with re

69 months, and 21 (66%) demonstrated a positive echocardiographic CRT response (>/=5% absolute increase

70 riables incrementally improved prediction of echocardiographic CRT response and survival beyond guide

71 Addition of exercise echocardiographic data (E/e' ratio>14) improved sensitiv

72 ity improvement (CQI) approaches to increase echocardiographic data accuracy and reliability.

73 asively proven HFpEF on the basis of resting echocardiographic data alone.

74 METHODS AND Demographic, clinical, and echocardiographic data at first presentation of 1992 pat

75 Clinical, electrocardiographic, and echocardiographic data from 90 subjects with PRKAG2 vari

76 We extracted clinical and echocardiographic data of all BAV subjects aged 0 to 20

77 Clinical and echocardiographic data were analyzed in overall populati

78 Clinical and echocardiographic data were analyzed retrospectively.

79 Patients in whom echocardiographic data were available both at baseline a

80 Echocardiographic data were available in 745 patients an

81 Demographic and echocardiographic data were collected.

82 Clinical, functional, and echocardiographic data were prospectively collected befo

83 In patients with available 3-year echocardiographic data, 1 had a mild paravalvular leak a

84 An independent core lab assessed all echocardiographic data, and an independent clinical even

85 of mortality among clinical, laboratory and echocardiographic data, we used cluster based hierarchic

86 o both cardiovascular magnetic resonance and echocardiographic data.

87 (National Echocardiographic Database of Australia [NEDA]; ACTRN126

88 Expert-annotated speckle-tracking echocardiographic datasets obtained from 77 ATH and 62 H

89 Non-invasive echocardiographic-derived index of LV stiffness may be i

90 Echocardiographic-derived profiling of LV forward flow,

91 ciated with LQTS increases the difficulty of echocardiographic diagnosis and decreases the likelihood

92 A total of 113 patients with an echocardiographic diagnosis of LVNC underwent CMR at 5 r

93 ppreciation of cardiac wall thickness, early echocardiographic diagnosis, and swift referral for card

94 However, the clinical and echocardiographic differences according to functional TR

95 Echocardiographic differences among HFpEF trials despite

96 elopment of defective systolic and diastolic echocardiographic/Doppler parameters developing in the h

97 LA stiffness was calculated as the ratio of echocardiographic E/e'-to-LA reservoir strain.

98 We performed a systematic and comprehensive echocardiographic evaluation of consecutive patients hos

99 ntral-line removal, and ophthalmological and echocardiographic evaluation to assess 90-day all-cause

100 tely powered prospective study with thorough echocardiographic evaluation will be critical.

101 d with COVID-19 infection underwent complete echocardiographic evaluation within 24 hours of admissio

102 A total of 2,555 patients had at least 2 echocardiographic evaluations and were eligible for BVD

103 drial ATP generation and was associated with echocardiographic evidence of diastolic dysfunction.

104 Early echocardiographic evidence of PVD after preterm birth in

105 on, recognition of discordant data within an echocardiographic examination, and proper interpretation

106 Cardiac imaging technicians performed the echocardiographic examinations and recorded right corona

107 Transthoracic echocardiographic examinations of 603 patients hospitali

108 In echocardiographic examinations of sufficient image quali

109 We sought to compare the quality of echocardiographic examinations performed at accredited v

110 Echocardiographic examinations revealed valve function w

111 Echocardiographic examinations were performed at 1- to 6

112 ed to evaluate the association between HF or echocardiographic exposures and VTE.

113 to low, intermediate, or high risk based on echocardiographic features at diagnosis.

114 whether patients with cryptogenic stroke and echocardiographic features representing risk of stroke w

115 In contrast, former smokers showed similar echocardiographic features when compared with never smok

116 covariates); comorbidities; medications; and echocardiographic features.

117 ts with LQTS, making it a routinely reported echocardiographic finding.

118 chronic lung disease, previous acute HF) and echocardiographic findings at discharge (grade III or IV

119 Demographic and clinical characteristics and echocardiographic findings at presentation, as well as c

120 Clinical and echocardiographic findings but not invasive hemodynamics

121 This study aimed to compare echocardiographic findings in low-risk patients with sev

122 nt and those who did not had similar overall echocardiographic findings, hemodynamics, 6MWD and NT-pr

123 a cardiac assist device and is compared with echocardiographic findings.

124 female) with paired post-procedure and late echocardiographic follow-up (median 5.8 years, range 5 t

125 lated hemodynamic valve deterioration during echocardiographic follow-up and/or SVD-related bioprosth

126 In the unmatched population, the 1-year echocardiographic follow-up demonstrated similar rate of

127 2 days (interquartile range, 76-996); median echocardiographic follow-up for patients that survived 1

128 using new standardized definitions based on echocardiographic follow-up of valve function, in interm

129 Mean echocardiographic follow-up was 20 +/- 13 months (minimu

130 Echocardiographic follow-up was available in 10 survivor

131 Three-year clinical and echocardiographic follow-up was obtained.

132 recent analysis involving a more systematic echocardiographic follow-up, the advent of transcatheter

133 RV function per echocardiographic fractional area change at presentation

134 contractile function using speckle-tracking echocardiographic global circumferential strain (GCS) fr

135 This study retrospectively compared echocardiographic GLS by speckle tracking at presentatio

136 of surgery type, TR decreased by at least 1 echocardiographic grade in 35.4%, 66.9%, and 92.8% of pa

137 3-year mean right ventricular outflow tract echocardiographic gradient was 15.7+/-5.5 mm Hg.

138 for PVI and LAPW ablation under intracardiac echocardiographic guidance.

139 safety and performance of a transesophageal echocardiographic-guided device designed to implant arti

140 ized these rats at the electrophysiological, echocardiographic, hemodynamic, morphological, cellular,

141 Of 824 patients with echocardiographic images to calculate Tei, pre-Tei was n

142 d age, sex, race, ethnicity, height, weight, echocardiographic images, and measurements performed at

143 Electrocardiograms, echocardiographic images, and videos presented in this r

144 assessment and management of PVL, including echocardiographic imaging and adjunctive techniques such

145 everity can be challenging with conventional echocardiographic imaging and may be better evaluated us

146 iew attempts to summarize the procedures and echocardiographic imaging used for transcatheter valve r

147 aluation based on clinical findings, precise echocardiographic imaging, and when necessary, adjunctiv

148 luation based on clinical findings, accurate echocardiographic imaging, and, when necessary, adjuncti

149 circulation and showed improvement in repeat echocardiographic imaging.

150 ardiographic progression and 45.2% and 46.3% echocardiographic improvement, respectively.

151 ch patient, and total isovolumic time is the echocardiographic index with the highest sensitivity to

152 n and reduced ejection fraction), as well as echocardiographic indicators of left ventricular remodel

153 e association between comorbidity burden and echocardiographic indicators of worse hemodynamics and r

154 Methods We compared echocardiographic indices of RV, neoaortic, and tricuspi

155 We used robust echocardiographic indices to characterize left ventricul

156 ating serum BDNF levels with two-dimensional echocardiographic indices will provide insights into the

157 The usefulness of echocardiographic indices, including those already used

158 h studies used similar protocol, centralized echocardiographic interpretation, and measures expressed

159 Further echocardiographic investigation led to the discovery of

160 Accredited echocardiographic laboratories had more complete reporti

161 It is presumed that echocardiographic laboratory accreditation leads to impr

162 ic regurgitation evaluated by an independent echocardiographic laboratory.

163 vice, or heart transplant, and (2) degree of echocardiographic left ventricular ejection fraction (LV

164 Echocardiographic left ventricular ejection fraction cha

165 Echocardiographic left ventricular end-systolic volume r

166 index, carotid intimal-medial thickness, and echocardiographic left ventricular hypertrophy and systo

167 io of LVWT to diastolic diameter, and higher echocardiographic LV ejection fraction than controls.

168 nstantaneous LV volumes were calculated from echocardiographic LV end-diastolic volume accounting for

169 Echocardiographic LV stiffness index was measured by a m

170 This study aimed to analyze echocardiographic manifestations in MIS-C.

171 ere and mild/moderate AS) according to their echocardiographic mean pressure gradient.

172 ltivariable model, RWT was the most powerful echocardiographic measure for estimating the risk of VAs

173 ntricular midwall strain represents a simple echocardiographic measure, which might be used for asses

174 Echocardiographic measurements (TA diameter, effective r

175 Echocardiographic measurements 28 days postimplantation

176 pediatric CCSs, to compare strain with other echocardiographic measurements and blood biomarkers, and

177 Published nomograms of pediatric echocardiographic measurements are limited by insufficie

178 ficant because interobserver variability for echocardiographic measurements are reported as >/=5% dif

179 Cardiac effects were assessed by echocardiographic measurements of left ventricular funct

180 Echocardiographic measurements of LV geometry and functi

181 ariable Cox regression and correlations with echocardiographic measurements performed.

182 Noninvasive echocardiographic measurements showed that left ventricu

183 Echocardiographic measurements showed that, although lep

184 -perfused hearts and in vivo hemodynamic and echocardiographic measurements, we demonstrate that ELA

185 erived measurements, being more precise than echocardiographic measurements, would advance our unders

186 c functionality was assessed by longitudinal echocardiographic measurements.

187 rglycemia along with significant deficits in echocardiographic measurements.

188 phics, body mass, and time between sleep and echocardiographic measurements.

189 n over clinical information and conventional echocardiographic measures for ischemic stroke in the AF

190 with incident HF, HF subtypes, and abnormal echocardiographic measures in the absence of clinical HF

191 modality approach that combines the relevant echocardiographic measures of diastolic function with bl

192 ve association between arsenic exposure with echocardiographic measures of left ventricular (LV) geom

193 e (Cerebral Performance Category score <=2), echocardiographic measures of left ventricular ejection

194 nd circulating adipokine concentrations with echocardiographic measures of LV mechanical function amo

195 For grade A TR signals, echocardiographic measures of systolic pulmonary arteria

196 d with deterioration in all the conventional echocardiographic measures of valve function assessed (e

197 Associations between HAART exposure and echocardiographic measures were evaluated using generali

198 association between apnea-hypopnea index and echocardiographic measures while accounting for the comp

199 ns of TTNtvs with diagnoses and quantitative echocardiographic measures, including subanalyses for in

200 eometries that are not assessable by current echocardiographic measures.

201 ent of AS severity in comparison to clinical echocardiographic measures.

202 roves survival, quality of life, and several echocardiographic measures.

203 ationale: Tissue Doppler imaging (TDI) is an echocardiographic method that measures the velocity of m

204 Multiple echocardiographic methods are used to measure left ventr

205 ed to cirrhosis can be assessed using robust echocardiographic methods.

206 However, in our cohort, current echocardiographic mTFC are not met by the majority of ad

207 Echocardiographic myocardial strain imaging is recommend

208 Patients who underwent an echocardiographic (n = 73) and cardiopulmonary exercise

209 Although the rates of echocardiographic normalization (30% and 27%) and heart

210 ifference in the proportion of children with echocardiographic normalization at 3 years of follow-up

211 mulative incidence of death, transplant, and echocardiographic normalization by cohort and to identif

212 s embryonic anomaly may be detected by fetal echocardiographic or newborn ultrasound examinations.

213 e effect of PPM implantation on clinical and echocardiographic outcomes after transcatheter aortic va

214 Clinical and echocardiographic outcomes are presented after 5 years.

215 HOT-CRT may improve clinical and echocardiographic outcomes in advanced heart failure pat

216 Clinical and echocardiographic outcomes of patients who underwent red

217 Clinical and echocardiographic outcomes were assessed at baseline, di

218 were followed for 2 years, and clinical and echocardiographic outcomes were assessed.

219 ears, 2 patients presented with an increased echocardiographic outflow gradient (1 mixed lesion with

220 cular myocardial performance index Tei is an echocardiographic parameter that incorporates the inform

221 Each echocardiographic parameter was determined to represent

222 stic information for VT/VF over clinical and echocardiographic parameters (C statistic 0.71 versus 0.

223 ality, after adjusting for age, clinical and echocardiographic parameters (HR 2.283 95% CI 1.318-3.96

224 There was no discordance when all the echocardiographic parameters agreed and high discordance

225 Primary outcomes were echocardiographic parameters and LV geometric patterns,

226 Echocardiographic parameters and New York Heart Associat

227 e mortality rate was 12%, with no changes in echocardiographic parameters and no cases of valve dysfu

228 C6, significantly negatively correlated with echocardiographic parameters for HOCM.

229 The study reviewed echocardiographic parameters in the acute phase of the M

230 By contrast, several echocardiographic parameters increased with increasing a

231 r CVD, B-type Natriuretic Peptide (BNP), and echocardiographic parameters of diastolic dysfunction.

232 The degree to which echocardiographic parameters of MR severity are concorda

233 There was limited concordance between the echocardiographic parameters of MR severity, and the dis

234 iated with worse outcome beyond conventional echocardiographic parameters of RV systolic function.

235 We aimed to define the changes in echocardiographic parameters of structure, function, and

236 the interaction between treatment group and echocardiographic parameters on clinical outcomes.

237 We evaluated changes in echocardiographic parameters over time, and used repeate

238 At 4 months of age, echocardiographic parameters revealed shortening of the

239 Combining BNP or NT-proBNP levels and echocardiographic parameters should help improve patient

240 nt of fluid responsiveness relies on dynamic echocardiographic parameters that have not yet been comp

241 Gastroenterology, CCM criteria consisted of echocardiographic parameters to identify subclinical car

242 mTFC echocardiographic parameters were analyzed, as well as c

243 raphy guidelines recommend assessing several echocardiographic parameters when evaluating mitral regu

244 Secondary endpoints included changes in echocardiographic parameters, overall mortality, the com

245 y was evaluated in dogs with PH by comparing echocardiographic parameters, quality-of-life (QOL) scor

246 Among echocardiographic parameters, we measured global longitu

247 sed M2 macrophage polarization, and improved echocardiographic parameters.

248 relationship between comorbidity burden and echocardiographic parameters.

249 articipants enrolled 4/1/2003-9/30/2012 with echocardiographic PASP measures.

250 he purpose of this study was to describe the echocardiographic patient qualification process for the

251 Second, echocardiographic PH (based on variable definitions) has

252 rtery systolic pressure (PASP) and prevalent echocardiographic PH.

253 rdiographic variables identified 3 different echocardiographic phenotypes of T2DM patients that were

254 burden of rheumatic heart disease (RHD) from echocardiographic population-based studies.

255 n a proposed alternative algorithm, the best echocardiographic predictors of a normal pulmonary arter

256 This analysis evaluated echocardiographic predictors of hypoattenuated leaflet t

257 h moderate-to-severe definite RHD, 47.6% had echocardiographic progression (including 2 deaths), and

258 inite and borderline RHD showed 26% and 9.8% echocardiographic progression and 45.2% and 46.3% echoca

259 te reporting and better image quality, while echocardiographic quantification and color Doppler image

260 Echocardiographic quantification of left ventricular (LV

261 ce of high-quality color Doppler imaging and echocardiographic quantification to improve the accuracy

262 ogression (including 2 deaths), and 9.5% had echocardiographic regression.

263 the important components of a comprehensive echocardiographic report.

264 Completeness and quality of echocardiographic reports and images were assessed by in

265 nical responders while 23 of 25 (92%) showed echocardiographic response.

266 -one patients had ABPM, and 142 patients had echocardiographic results available for analysis.

267 external laboratory accreditation status and echocardiographic results.

268 tal prognostic information over clinical and echocardiographic risk factors in predicting ventricular

269 ared with a model with clinical and standard echocardiographic risk factors.

270 We aimed to develop a simple echocardiographic score applicable for RHD screening wit

271 ing and implementation, EMW correlation from echocardiographic sonographers showed excellent reliabil

272 Echocardiographic studies before and 12+/-1 months after

273 he accuracy, reproducibility, and quality of echocardiographic studies for valvular heart disease.

274 Echocardiographic studies included left ventricular (LV)

275 re with preserved ejection fraction (HFpEF), echocardiographic studies suggest that global longitudin

276 cally estimate LVEF on a database of >50 000 echocardiographic studies, including multiple apical 2-

277 artile range: 8 to 34 years) with periodical echocardiographic studies.

278 METHODS AND We conducted a prospective echocardiographic study in 756 healthy children (aged 1

279 uthors performed a combined mathematical and echocardiographic study to understand the inconsistencie

280 A comprehensive baseline echocardiographic study was performed at the clinician s

281 mpared with GDMT alone was consistent in all echocardiographic subgroups, independent of the severity

282 f the 6 proteins, pQTLs were associated with echocardiographic traits (P<0.0006) in EchoGen, and for

283 ed associations between the QRS variants and echocardiographic traits and cardiovascular diseases, in

284 asma levels of 1305 proteins were related to echocardiographic traits and to incident HF using multiv

285 Seventeen proteins associated with echocardiographic traits in cross-sectional analyses (fa

286 of these proteins had pQTLs associated with echocardiographic traits in EchoGen (P<0.0007).

287 ating protein levels (pQTLs) were related to echocardiographic traits in the EchoGen (n=30 201) and t

288 A GWAS meta-analysis of echocardiographic traits was performed, including 46,533

289 med COVID-19 who had undergone transthoracic echocardiographic (TTE) and electrocardiographic evaluat

290 Transthoracic echocardiographic (TTE) surveillance of patients with mi

291 r complications, bleeding complications, and echocardiographic valve parameters.

292 covariates to assess the association between echocardiographic variables and SCD, adjusting for Frami

293 Cluster analysis of echocardiographic variables identified 3 different echoc

294 A cluster analysis was performed on echocardiographic variables, and the association between

295 ts with adjustment for multiple clinical and echocardiographic variables.

296 the risk of VAs compared with commonly used echocardiographic variables.

297 , which improved to 96.2% with addition of 4 echocardiographic variables.

298 convolutional neural network model evaluated echocardiographic videos from 4 standard views, before a

299 The echocardiographic visualization of transpulmonary agitat

300 Echocardiographic Z scores based on BSA were derived fro